In a 75-year-old, 47‑kg woman who has received intrathecal morphine, when should naloxone be administered for opioid‑induced respiratory depression?

When to Administer Naloxone for Intrathecal Morphine-Induced Respiratory Depression

Naloxone should be administered immediately when significant respiratory depression occurs after intrathecal morphine, defined as respiratory rate <10 breaths/min and/or oxygen saturation <90%, particularly in this high-risk 75-year-old, low-weight patient. 1

Immediate Indications for Naloxone

Administer naloxone for any of the following:

• Respiratory rate <10 breaths per minute 1
• Oxygen saturation <90% 1
• Altered level of consciousness with respiratory compromise 1
• Severe respiratory depression with signs of inadequate ventilation 2

The ASA guidelines explicitly state that reversal agents should be administered to all patients experiencing significant respiratory depression after neuraxial opioid administration. 1

Specific Dosing for This Patient

Given this patient's advanced age (75 years), low body weight (47 kg), and intrathecal morphine administration, use careful titration:

Initial approach:

• Start with 0.1-0.2 mg IV naloxone given slowly over 2-3 minutes 3
• Titrate to adequate ventilation and alertness, not complete opioid reversal 3
• Repeat every 2-3 minutes as needed until respiratory function normalizes 2, 3

Critical dosing considerations:

• Avoid bolus dosing in patients on chronic opioids, as this causes refractory pain and withdrawal 4
• For postoperative patients like this one, smaller incremental doses (0.1-0.2 mg) are preferred over larger doses (0.4-2 mg used for acute overdose) 3
• The goal is reversal of respiratory depression while maintaining some analgesia 4

High-Risk Patient Factors

This 75-year-old, 47-kg woman has multiple risk factors requiring heightened vigilance:

• Advanced age - extremes of age increase respiratory depression risk 1
• Low body weight - may have received relatively higher dose per kg 1
• Intrathecal morphine specifically - hydrophilic opioids like morphine have delayed, prolonged respiratory depression risk (up to 24-48 hours) compared to lipophilic agents like fentanyl 1, 5

Stepwise Management Algorithm

Before naloxone administration:

1. Provide supplemental oxygen immediately 1
2. Attempt verbal and physical stimulation 4
3. Ensure patent airway and consider assisted ventilation if severe 2

Naloxone administration:

1. Give 0.1-0.2 mg IV slowly over 2-3 minutes 3
2. Assess response (respiratory rate, oxygen saturation, level of consciousness)
3. Repeat dose every 2-3 minutes until adequate ventilation achieved 2, 3
4. If no response after 10 mg total, question the diagnosis 3

Post-reversal management:

1. Maintain continuous surveillance - naloxone half-life (~33 minutes) is much shorter than intrathecal morphine duration (hours to days) 2, 6, 7
2. Prepare for repeated dosing or continuous infusion - renarcotization is common 2, 3
3. Consider naloxone infusion: 2 mg in 500 mL (0.004 mg/mL) titrated to effect 3
4. Maintain IV access for recurring respiratory depression 1

Critical Pitfalls to Avoid

Do not give excessive naloxone doses:

• Larger than necessary doses cause complete analgesia reversal, hypertension, tachycardia, nausea, vomiting, and circulatory stress 3
• Too rapid reversal precipitates acute opioid withdrawal 3

Do not assume single dose is sufficient:

• Intrathecal morphine can cause delayed respiratory depression up to 24-48 hours post-administration 1, 5
• Duration of morphine effect exceeds naloxone duration, requiring repeated doses or infusion 2, 6

Consider intrathecal naloxone for refractory cases:

• One case report showed parenteral naloxone failed to reverse intrathecal morphine-induced respiratory depression, but 0.1 mg intrathecal naloxone produced prompt reversal 8
• This remains an option if standard IV naloxone is ineffective 8

Monitoring Requirements

Extended monitoring is mandatory:

• Monitor respiratory rate and oxygen saturation at least every 4 hours for minimum 48 hours after intrathecal morphine 1
• This patient requires increased monitoring intensity due to age and risk factors 1
• Continue monitoring beyond initial naloxone response due to renarcotization risk 2, 3